Recent Updates
Recently added Catalysts

DTaP-IPV-HB-PRP~T combined vaccine

Phase 3

Haemophilus Influenzae Type b Immunisation | Vaccines | Other |Sanofi|Trials Updated: Nov 17, 2026

DTaP-IPV-HB-PRP~T combined vaccine development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment720

FDA Designations

No designations recorded

DTaP-IPV-HB-PRP~T combined vaccine clinical trials

DTaP-IPV-HB-PRP~T combined vaccine · 1 trial · 7 indications

Phase 3 1
NCT07941622Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.Haemophilus Influenzae Type b Immunisation
NOT YET_RECRUITING720 Analytics
PHASE3NOT YET_RECRUITING
Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.
Haemophilus Influenzae Type b ImmunisationUnlock trial analytics

Study Endpoints

Primary Endpoints

1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Day181

Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA

Secondary Endpoints

Baseline, pre-vaccination sample
Day 31
1 month after the last dose of primary series:
Day181
Before the booster dose:
Day 511
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Group 1 (the investigational group)EXPERIMENTALHexaxim at 2, 4 and 6 MoA
Group 2 (the comparator group)ACTIVE_COMPARATORPentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

Interventions

NameTypeDescription
DTaP-IPV-HB-PRP~T combined vaccineBIOLOGICALPharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection
DTaP-IPV//PRP~T combined vaccineBIOLOGICALPharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection
monovalent Hep B vaccineBIOLOGICALPharmaceutical form: Depending on the brand procured Route of administration:IM injection
Unlock Study Design Details

Eligibility Criteria

Age Range30 Days to 45 Days
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine * Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (\>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, an...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 17, 2026NCT07941622NEW_TRIAL: changed
LOWNov 17, 2026NCT07941622NEW_TRIAL: changed